- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06387342
Namodenoson Treatment of Advanced Pancreatic Cancer
May 1, 2024 updated by: Can-Fite BioPharma
CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma
This is an open-label trial in patients with advanced pancreatic cancer.
The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
All patients will receive the study drug twice daily.
The study drug is given as a capsule, orally (by mouth).
Patients will be monitored regularly for safety.
Tumor imaging will be performed approximately every two months.
Patients can decide to stop the treatment with study drug at any time.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zivit Harpaz
- Phone Number: +972 3 924 1114
- Email: Zivit@canfite.co.il
Study Locations
-
-
-
Petach Tikva, Israel, 49100
- Rabin Medical Center Institute of Oncology
-
Contact:
- Salomon M Stemmer, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Males and females at least 18 years of age.
- Histologically or cytologically confirmed pancreatic adenocarcinoma, or clinically diagnosed based upon scan results and a serum Cancer Antigen 19-9 value >1000 U/mL on at least 1 occasion.
- Pancreatic adenocarcinoma is advanced (i.e., treatment-refractory or metastatic) and no standard therapies are expected to be curative.
- Pancreatic adenocarcinoma has progressed on at least 1 prior systemic treatment regimen, or the patient refuses standard treatment.
- Prior pancreatic adenocarcinoma treatment was discontinued for at least 14 days prior to the Baseline Visit.
- Measurable or evaluable disease by RECIST v1.1.
- Patients with a history of treated central nervous system (CNS) metastases are eligible, provided they meet all of the following criteria: disease outside the CNS is present; there is no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study; and there is no history of intracranial hemorrhage or spinal cord hemorrhage.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of ≤ 2.
The following laboratory values must be documented prior to the first dose of study drug:
- Absolute neutrophil count (ANC) ≥1.5 × 109/L
- Platelet count ≥50 × 109/L
- Creatinine clearance ≥50 mL/min (estimated glomerular filtration rate by the Cockcroft-Gault) or serum creatinine ≤2.0 mg/dL
- Aspartate aminotransferase (AST) and Alanine transaminase (ALT) ≤10X the upper limit of normal
- Total bilirubin ≤10 mg/dL
- Serum albumin ≥2.0 g/dL.
- Life expectancy of ≥8 weeks.
- For women of childbearing potential, negative serum pregnancy test result.
- Provide written informed consent to participate.
- Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other trial-related procedures
Exclusion Criteria:
- Receipt of systemic cancer therapy within 14 days prior to the Baseline Visit or concurrently during the trial.
- Persistent toxicity ≥Grade 2 from previous cancer therapy, with the exceptions of alopecia and Grade 3 peripheral neuropathy.
- Major surgery or radiation therapy within 14 days prior to the Baseline Visit.
- Use of any investigational agent within the shorter of 4 weeks or 5 half-lives prior to the Baseline Visit.
- Concomitant use of P-glycoprotein (P-gp)/breast cancer resistance protein (BCRP) inhibitors and/or substrates with a narrow therapeutic index unless the medication can be taken at least 3 hours before or after taking the investigational product.
- Unable to swallow orally administered medication or presence of a gastrointestinal disorder likely to interfere with absorption of the study medication.
- Uncontrolled or clinically unstable thyroid disease, per judgment of the Principal Investigator.
- Active bacterial, viral, or fungal infection requiring systemic therapy or operative or radiological intervention.
- Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness or other immunodeficiency.
- Active second primary malignancy (other than pancreatic adenocarcinoma) requiring treatment.
- Uncontrolled arterial hypertension or congestive heart failure (New York Heart Association Classification 3 or 4).
- Angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 1 month prior to initiation of study drug.
- History of, or ongoing, cardiac dysrhythmias requiring treatment, atrial fibrillation of any grade, or persistent prolongation of the corrected QT interval (QTc) (Fridericia) interval to >470 msec [mean of triplicate electrocardiogram measurements] (patients with bundle branch block or a cardiac pacemaker will not be excluded for QTc reasons).
- Pregnant or lactating female.
- Women of childbearing potential, unless they agree to use dual contraceptive methods which, in the opinion of the Investigator, are effective and adequate for the patient's circumstances while on study drug and for at least 1 month thereafter.
- Men who partner with a woman of childbearing potential, unless they agree to use effective, dual contraceptive methods (i.e., a condom, with female partner using oral, injectable, or barrier method) while on study drug and for 1 month afterward.
- Any severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with trial participation or study drug administration; may interfere with the informed consent process and/or with compliance with the requirements of the trial; or may interfere with the interpretation of trial results and, in the Investigator's opinion, would make the patient inappropriate for entry into this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Namodenoson 25 mg
namodenoson capsule, 25 mg, administered orally, twice daily for consecutive 28-day cycles
|
oral capsule
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline
Time Frame: Every 2 weeks, assessed up to 1 year
|
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), which is a scale of functioning, from 0 (normal activity) to 5 (death)
|
Every 2 weeks, assessed up to 1 year
|
Adverse Events
Time Frame: Every 2 weeks, assessed up to 1 year
|
Assessments of adverse events (AEs) will include characterization of type, incidence, severity (graded by CTCAE v5.0), seriousness, and relationship to treatment.
|
Every 2 weeks, assessed up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: Every 8 weeks, assessed up to 1 year
|
clinical activity measure of objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), measured by computed tomography (CT) scan, positron emission tomography (PET) CT, and/or magnetic resonance imaging (MRI)
|
Every 8 weeks, assessed up to 1 year
|
Progression free survival
Time Frame: Every 8 weeks, assessed up to 1 year
|
clinical activity measure of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), measured by computed tomography (CT) scan, positron emission tomography (PET) CT, and/or magnetic resonance imaging (MRI)
|
Every 8 weeks, assessed up to 1 year
|
Disease control rate
Time Frame: Every 8 weeks, assessed up to 1 year
|
clinical activity measure of disease control rate (DCR)
|
Every 8 weeks, assessed up to 1 year
|
Duration of response
Time Frame: Every 8 weeks, assessed up to 1 year
|
clinical activity measure of duration of response (DoR), defined as the time from first response to disease progression or death from any cause, whichever occurs first
|
Every 8 weeks, assessed up to 1 year
|
Overall survival
Time Frame: Every 8 weeks, assessed up to 1 year
|
clinical activity measure of overall survival (OS), including death from any cause
|
Every 8 weeks, assessed up to 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life evaluation with EORTC QLQ-C30
Time Frame: Every 4 weeks, assessed up to 1 year
|
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30), in which summary scores range from 0 to 100, with higher scores indicating better health-related quality of life
|
Every 4 weeks, assessed up to 1 year
|
Quality of Life evaluation with EORTC QLQ-PAN26
Time Frame: Every 4 weeks, assessed up to 1 year
|
European Organization for Research and Treatment of Cancer Quality of Life pancreatic adenocarcinoma-specific module, the EORTC QLQ-PAN26, in which summary scores range from 0 to 100, with higher scores indicating better health-related quality of life
|
Every 4 weeks, assessed up to 1 year
|
Pharmacokinetics of namodenoson: Cmax
Time Frame: Cycle 1, day 1 (each cycle is 28 days); Cycle 1, day 15, and Cycle 2, day 1
|
Maximum plasma concentration of namodenoson
|
Cycle 1, day 1 (each cycle is 28 days); Cycle 1, day 15, and Cycle 2, day 1
|
Pharmacokinetics of namodenoson: Cmin
Time Frame: Cycle 1, day 1 (each cycle is 28 days); Cycle 1, day 15, and Cycle 2, day 1
|
Minimum plasma concentration of namodenoson
|
Cycle 1, day 1 (each cycle is 28 days); Cycle 1, day 15, and Cycle 2, day 1
|
Pharmacokinetics of namodenoson: AUC(0-12)
Time Frame: Cycle 1, day 1 (each cycle is 28 days); Cycle 1, day 15, and Cycle 2, day 1
|
Area under the curve of namodenoson plasma exposure from 0-12 hours post-dose
|
Cycle 1, day 1 (each cycle is 28 days); Cycle 1, day 15, and Cycle 2, day 1
|
Cancer antigen 19-9 (CA 19-9)
Time Frame: Every 4 weeks, assessed up to 1 year
|
Change from baseline in Cancer antigen 19-9 (CA 19-9) biomarker during treatment
|
Every 4 weeks, assessed up to 1 year
|
Carcinoembryonic Antigen (CEA)
Time Frame: Every 4 weeks, assessed up to 1 year
|
Change from baseline in Carcinoembryonic Antigen (CEA) biomarker during treatment
|
Every 4 weeks, assessed up to 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Michael H Silverman, MD, Can-Fite BioPharma
- Principal Investigator: Salomon M Stemmer, MD, Rabin Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.
- Modi S, Kir D, Banerjee S, Saluja A. Control of Apoptosis in Treatment and Biology of Pancreatic Cancer. J Cell Biochem. 2016 Feb;117(2):279-88. doi: 10.1002/jcb.25284.
- Mazziotta C, Rotondo JC, Lanzillotti C, Campione G, Martini F, Tognon M. Cancer biology and molecular genetics of A3 adenosine receptor. Oncogene. 2022 Jan;41(3):301-308. doi: 10.1038/s41388-021-02090-z. Epub 2021 Nov 8.
- Itzhak I, Bareket-Samish A, Fishman P. Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/beta-catenin, NF-kappaB, and RAS Signaling Pathways. Biomolecules. 2023 Oct 27;13(11):1584. doi: 10.3390/biom13111584.
- Li L, Mo FK, Chan SL, Hui EP, Tang NS, Koh J, Leung LK, Poon AN, Hui J, Chu CM, Lee KF, Ma BB, Lai PB, Chan AT, Yu SC, Yeo W. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. BMC Cancer. 2017 Jan 4;17(1):8. doi: 10.1186/s12885-016-2995-5.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 15, 2024
Primary Completion (Estimated)
July 15, 2026
Study Completion (Estimated)
December 15, 2026
Study Registration Dates
First Submitted
April 15, 2024
First Submitted That Met QC Criteria
April 26, 2024
First Posted (Actual)
April 29, 2024
Study Record Updates
Last Update Posted (Actual)
May 2, 2024
Last Update Submitted That Met QC Criteria
May 1, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CF102-222PC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsKorea, Republic of, United States, Japan
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
Clinical Trials on Namodenoson 25mg
-
Can-Fite BioPharmaRecruitingNASH - Nonalcoholic SteatohepatitisIsrael, Bosnia and Herzegovina, Bulgaria, Moldova, Republic of, Romania, Serbia
-
Can-Fite BioPharmaRecruitingHepatocellular Carcinoma | CirrhosisUnited States, Bosnia and Herzegovina, Bulgaria, Israel, Moldova, Republic of, Poland, Romania, Serbia, Slovakia
-
Sihuan Pharmaceutical Holdings Group Ltd.Unknown
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownDiabetic Peripheral Neuropathy
-
Idorsia Pharmaceuticals Ltd.Janssen Biotech, Inc.Completed
-
AstraZenecaCompleted
-
Percheron TherapeuticsRecruitingDuchenne Muscular DystrophyTurkey, United Kingdom, Australia, Serbia, Bulgaria
-
Haisco Pharmaceutical Group Co., Ltd.Completed
-
Ascletis Pharmaceuticals Co., Ltd.Completed
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedDiabetic Neuropathy PeripheralChina